NCT07542782Completed
Pancreatic Resection in Fit Octogenarians With Nonmetastatic Pancreatic Cancer
Pancreatic Resection in Fit Octogenarians With Nonmetastatic Pancreatic Cancer: A Population-Based Survival Analysis
Source: ClinicalTrials.gov · Last updated 21 Apr 2026
Brief summary (registry, in English)
This study looks at how different treatment approaches affect survival in older people with pancreatic cancer that has not spread to other parts of the body. In particular, it focuses on patients aged 80 years and older who are still in relatively good general health and able to carry out normal daily activities. Pancreatic cancer is a serious disease, and surgery to remove the tumor is often the only treatment that offers a chance of longer survival. However, older patients are less likely to receive surgery, even if they are otherwise fit. Doctors may hesitate to recommend surgery mainly because of the patient's age, rather than their overall health condition. This study aims to better understand whether surgery can still be beneficial for these older patients. The study also examines the role of additional treatment after surgery, such as chemotherapy. In real-world medical practice, not all patients receive this follow-up treatment, especially older individuals who may have a slower recovery after surgery. This can make it difficult to understand whether such treatments truly improve survival. To answer these questions, the study uses data from a large cancer registry in Germany. It compares patients who had surgery with those who did not, and it also looks at patients who received additional treatment after surgery versus those who did not. Special methods are used to take into account that some patients may not have been able to receive further treatment because they did not recover well enough after surgery. The results of this study are intended to help doctors make better treatment decisions for older patients with pancreatic cancer, focusing more on their overall health and less on age alone.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 2048 (actual)
- First submitted
- 15 Apr 2026
- Start date
- 1 Jan 2017
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Medizinische Hochschule Brandenburg Theodor Fontane
- Diseases
- Pancreatic cancer
- NCT number
- NCT07542782
What you commit to
- Study type: Observational
- Participants enrolled: 2048
- From 1 Jan 2017 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Neuroendocrine tumors
- Sarcomas
Who the study is looking for
- Diagnosis of invasive pancreatic carcinoma
- UICC stage I-III
- No distant metastases (M0)
- ECOG performance status 0-1
- Diagnosis between Jan 1, 2017 and Dec 31, 2023
- Residence in Berlin or Brandenburg
Age in the registry: 18 years to 89 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical School Brandenburg Coordinator of this site? Confirm its status | Brandenburg an der Havel | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.